Table 1:

Drug-drug interactions of antiretrovirals with rifampicin and rifabutin

	Rifampicin		Rifabutin
Antiretroviral	Effect	Dose adjustment and comments	Effect	Dose adjustment and comments
NNRTI
NVP	↓↓NVP	Avoid concomitant use	↓RBT	Can be co-administered with RBT 300 mg once daily
EFV	↓/= EFV	EFV 600 mg can be co-administered without dose adjustments Non-significant changes in EFV 400mg exposure in a small clinical PK study[35]	↓RBT	Can be co-administered with RBT 450 mg once daily
RPV	↓↓RPV	Avoid concomitant use	↓RPV	Avoid concomitant use When necessary, can be co-administered with RPV 50 mg once daily with caution (ECG monitoring due to risk of QT prolongation)
ETR	↓↓ETR	Avoid concomitant use	↓ETR	Can be co-administered without dose adjustments Limited data available
DOR	↓↓DOR	Avoid concomitant use	↓DOR	Can be co-administered with DOR 100 mg twice daily Limited data available derived only from PK studies
PI
LPV/r	↓↓LPV/r	Avoid concomitant use	↑RBT	Can be co-administered with RBT 150 mg once daily Monitor closely due to potential increased RBT toxicity
ATV/r	↓↓ATV/r		↑RBT
DRV/r	↓↓DRV/r		↑RBT
Boosters
Cobi	↓↓Cobi	Avoid concomitant use	↓↓Cobi	Avoid concomitant use
INSTI
RAL	↓RAL	Can be co-administered with RAL 400 or 800 mg twice daily Avoid RAL 1200 mg once-daily dose	= RAL	Can be co-administered with RBT 300 mg once daily, RAL standard dose
EVG/c	↓↓EVG/c	Avoid concomitant use	↓EVG/c ↑RBT	Avoid concomitant use
DTG	↓DTG	Can be co-administered with DTG 50 mg twice daily	= DTG	Can be co-administered with RBT 300 mg once daily
BIC	↓↓BIC	Avoid concomitant use	↓BIC	Avoid concomitant use No data available
NRTI
TDF, ABC, 3TC, FTC	=TDF =ABC =3TC =FTC	Can be co-administered without dose adjustments	=TDF =ABC =3TC =FTC	Can be co-administered without dose adjustments
TAF	↓↓TAF	Co-administration with TAF 25 mg once daily resulted in non-significant changes in intracellular tenofovir diphosphate exposure in an healthy volunteer PK study [21]	↓TAF	Avoid concomitant use until further data available
CCR5 receptor antagonists
MVC	↓↓MVC	Can be co-administered with MVC 600 mg twice daily	↓MVC	Can be co-administered without dose adjustments

NNRTIs, non-nucleoside reverse transcriptase inhibitors; NVP, nevirapine; EFV, efavirenz; RPV, rilpivirine; ETR, etravirine; DOR, doravirine; PIs, protease inhibitors; LPV, lopinavir; ATV, atazanavir, DRV, darunavir;/r, ritonavir; cobi, cobicistat; INSTIs, integrase inhibitors; RAL, raltegravir; EVG, elvitegravir; DTG, dolutegravir; BIC, bictegravir; NRTIs, nucleoside reverse transcriptase inhibitors; TDF, tenofovir disoproxil fumarate; ABC, abacavir; 3TC, lamivudine; FTC, emtricitabine; TAF, tenofovir alafenamide; MVC, maraviroc; PK, pharmacokinetic; RBT, rifabutin